Dr. Ron Gasbarro
Rx-Press
East Lake Road
New Milford, PA 18834
(570) 465-2838
eMail Ron here
The following list contains a selection of manuscripts in which I provided editorial assistance, that is, I supplied structure, research, organization, referencing, and other activities necessary to get the article into publishable form.
| Manuscript title and publication information |
| Arrieta AC, Bradley JS. Empiric use of cefepime in the treatment of serious urinary tract infections in children. Pediatr Infect Dis J. 2001;20:350-5. |
| Barrie AM III, Plevy SE. The interleukin-12 family of cytokines: Therapeutic targets for inflammatory disease mediation. Clin Applied Immunol Rev. 2005;e225-40. |
| Blumer JL, Reed MD, Knupp C. Review of the pharmacokinetics of cefepime in children. Pediatr Infect Dis J. 2001;20:337-42. |
| Bradley JS, Arrieta A. Empiric use of cefepime in the treatment of lower respiratory tract infections in children. Pediatr Infect Dis J. 2001;20:343-9. |
| Campos C. Narrowing the cultural divide in diabetes mellitus care: a focus on improving cultural competency to better serve Hispanic/Latino populations. Insulin. 2006;1:70-6. |
| Cannon CP. The endocannabinoid system: a new approach to control cardiovascular disease. Clin Cornerstone. 2005;7:17-26. |
| Cohen C. First-line treatment in HIV: many paths to success. JAIDS. 2003;33:S29-38. |
| Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology. 2000;55(12 Suppl 5):S15-21. |
| Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10:298-305. |
| Dardick K. Educating travelers about malaria: dealing with resistance and patient noncompliance.Cleve Clin J Med. 2002; 69:469-79. (Download) |
|
Davila GW. Transdermal oxybutynin: a new treatment for overactive
bladder. |
| Hernandez JD, Wesseling K, Salusky IB. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial. 2005;18:290-5. |
| Jones SE. Antiaromatase agents: evolving role in adjuvant therapy. Clin Breast Cancer. 2002;3:33–42. |
| Lasseter KC, Dilzer SC, Vargas R, Waldman S, Noveck RJ. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clin Pharmacokinet. 2004;43:121-9. |
| Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182-7. |
| Moyle GJ. Protease inhibitor-sparing regimens: new evidence strengthens position. JAIDS. 2003;33:S17-25. |
| Murphy RL. Reviving protease inhibitors:
new data and more options. JAIDS. 2003;33:S43-52. |
| Neutel JM. The importance of 24-h blood pressure control. Blood Press Monit. 2001;6:9-16. |
| Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther. 2002;24 (Suppl C):C43-57. |
| Powderly WG. Limitations of current HIV therapies: opportunities for improvement. JAIDS. 2003;33:S7-12. |
| Ratner PH, Lim JC, Georges GC. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol. 2000;105(6 Pt 1):1101-7. |
| Saez-Llorens X, O'Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J. 2001;20:356-61. |
| Schiff ER, de Medina M, Kahn RS. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis. 1999;19 (Suppl 1):3-15. |
| Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al; for Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005;115:1030-8. |
| Stotland NL. Overcoming psychological barriers in insulin therapy. Insulin. 2006;1:38-45. |
|
Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother. 2004;54:515-23. |
| Vinik AI. The metabolic basis of atherogenic dyslipidemia. Clin Cornerstone. 2005;7:27-35 |
|
Watts RL, Raiser CD, Stover NP, Cornfeldt ML, Schweikert AW, Allen RC, Subramanian T, Doudet D, Honey CR, Bakay RA. Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease. J Neural Transm Suppl. 2003;215-27. |
| Weir MR. The role of multiple drug therapy for controlling hypertension in African Americans. J Clin Hypertens (Greenwich). 2000;2:99-108. |
Many more manuscripts are in the pre-published stage and involve the following disease stages and/or agent classes:
|
Adult ADHD |
Cervical cancer |
Sleep disorders/ Narcolepsy |
Rheumatoid arthritis |
|
Colorectal cancer |
Stroke |
Contraception |
Growth hormone |
|
Diabetes pathophysiology |
Psoriasis |
Schizophrenia |
Asthma |
